A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)
NUC-011/BIO
Phase 1 other active
Quick answer
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC) for Primary Sclerosing Cholangitis (PSC) is a Phase 1 program (other) at Dr. Falk Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Dr. Falk Pharma GmbH
- Indication
- Primary Sclerosing Cholangitis (PSC)
- Phase
- Phase 1
- Modality
- other
- Status
- active